Imugene Ltd has released a press release.
Response to ASX Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Research partnership with Celularity for solid tumors
- Prospectus for SPP and Placement Options Offer
- Imugene completes $90 M placement and launches $5 M SPP
- Appendix 4C - Quarterly Report
- FDA ind approval of new oncolytic virotherapy checkvacc
Later from Imugene
- Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx
- Appendix 4E and Full Year Statutory Accounts
- Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials
- S&P DJI Announces September 2021 Quarterly Rebalance
- Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene